Why Indivior Pharmaceuticals Stock Topped the Market Today
The company is merging with a peer.
Indivior Pharmaceuticals (INDV) experienced a positive trading session on Monday as its merger with Supernus Pharmaceuticals (SUPN) closed successfully. The merger created a diversified central nervous system (CNS) biopharmaceutical company, as stated by Indivior. Supernus investors received nearly 1.5 shares of Indivior's common stock for each Supernus share they owned, while Indivior investors were paid a one-time special cash dividend of $1 billion before the merger's close.
Post-merger, Indivior investors were set to hold approximately 56.5% of the combined healthcare business, with Supernus investors holding the remaining 43.5%. The companies aimed to achieve $125 million in annual cost synergies through the partnership. Investors should monitor the new Supernus' cost evolution to determine the effectiveness of management in realizing the expected synergies.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
